CD274 and hepatocellular carcinoma: However, more recently, the combination of atezolizumab (anti-PD-L1) and bevacizumab (anti-VEGF) demonstrated better outcomes than sorafenib, with an overall survival of 19 months in patients with advanced HCC [8].